A Phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia

Cancer

Volumn 86, Issue 11, 1999, Pages 2246-2251

  Koller, Charles A ^a   Kantarjian, Hagop M ^a   Feldman, Eric J ^b   O'Brien, Susan ^a   Rios, Mary Beth ^a   Estey, Elihu ^a   Keating, Michael ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Acute lymphoblastic leukemia; Acute myelogenous leukemia; Blastic phase of chronic myelogenous leukemia; Cytarabine; Fludarabine; Mitoxantrone; Reinduction regimens

Indexed keywords

ANTILEUKEMIC AGENT; CYTARABINE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLAST CELL CRISIS; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; LEUKEMIA REMISSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; CYTARABINE; DNA DAMAGE; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MITOXANTRONE; SALVAGE THERAPY; TREATMENT OUTCOME; VIDARABINE;

EID: 0033404947     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991201)86:11<2246::AID-CNCR11>3.0.CO;2-I     Document Type: Article

References (17)

1. Estey E, deLima M, Strom S, Pierce S, Freireich EJ, Keating MJ. Long-term follow-up of patients with newly diagnosed acute myelogenous leukemia treated at The University of Texas M. D. Anderson Cancer Center. Cancer 1997;80(11 Suppl):2176-80.
2. Champlin R, Gale RP. Acute myelogenous leukemia: recent advances in therapy. Blood 1987;69:1551-62.
3. Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989;7:1071-80.
4. Welborn JL. Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults. Am J Hematol 1994;45:341-4.
5. Schiller G, Gajewski J, Territo M, Nimer S, Lee M, Belin T, et al. Long-term outcome of high-dose cytarabine-based consolidation therapy for adults with acute myelogenous leukemia. Blood 1992;80:2977-82.
6. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MI. Fludarabine and arabinosyl cytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 1993;11:343-50.
7. Gandhi V, Estey E, Keating MJ, Plunkett W. Biochemical modulation of arabinosylcytosine for therapy of leukemias [review]. Leuk Lymphoma 1993;10 Suppl:109-14.
8. Feldman EJ, Seiter K, Damon L, Linker C, Rugo H, Ries C, et al. A randomized trial of high- vs. standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia 1997;11:485-9.
9. Feldman EJ, Alberts D, Arlin A, Ahmed T, Mittelman A, Baskind P, et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993; 11:2002-9.
10. Alberts DS, Young L, Mason N, Salmon SE. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 1985;12(3 Suppl 4):38-42.
11. Grant S, Arlin Z, Gewitz D. Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors. Leukemia 1991;5:336-9.
12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of the acute myeloid leukemia: a report of the French-American-British (FAB) Co-Operative Group. Ann Intern Med 1985;103:620.
13. Gandhi V, Estey E, Keating M, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993; 11:116-24.
14. Kantarjian HM, O'Brien SM, Keating M, Beran M, Estey E, Giralt S, et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 1997;11:1617-20.
15. Montillo M, Tedeschi A, Centurioni R, Leoni P. Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF). Leuk Lymphoma 1997; 25:579-83.
16. Moore JO, Olsen GA. Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Semin Oncol 1984; 11(Suppl 1):41-6.
17. Lejeune C, Tubiana N, Gastaut JA, Maraninchi D, Richard B, Launay MC, et al. High-dose cytosine arabinoside and mitoxantrone in previously treated acute leukemia patients. Eur J Haematol 1990;44:240-3.